The aim of this study is to reveal the causal relationship between dilated cardiomyopathy and aldosteronoma. A 44-yearold male dilated cardiomyopathy patient with aldosteronoma, who demonstrated a worse cardiac function after 1 year therapy with optimized dosage of sacubirtil/valsartan, furosemide, metoprolol, and spironolactone. The patient shows a promising prognosis after aldosteronoma removal procedure. Aldosteronoma may cause dilated cardiomyopathy. We assume that the optimal treatment for aldosteronoma-induced dilated cardiomyopathy is surgical removal combined with drugs.
Introduction
Primary hyperaldosteronism caused by aldosteronoma has not yet been reported as a cause of dilated cardiomyopathy. Dilated cardiomyopathy, characterized by left ventricular (LV) dilation and systolic dysfunction, is one of the common causes of heart failure with reduced ejection fraction (EF) with a prevalence of approximately 1:2500 in the general population [1] [2] [3] . Aldosteronoma is a tumour generating excess aldosterone leading to primary aldosteronism, reported in more than 11% of involved hypertensive patients, causing severe high blood pressure, even an increased risk of heart attack, stroke, or an irregular heartbeat. 4, 5 Here, we report an aldosteronoma-induced case of dilated cardiomyopathy.
Case presentation
In September 2018, a 44-year-old male patient with a history of hypertension for 10 years, who started on sacubitril/valsartan at the dosage of 100 mg bid 6 months ago, was referred to our hospital with typical signs of paroxysmal nocturnal dyspnoea. Echocardiography showed severe LV dilation [LV end-diastolic diameter (EDD) 72 mm] with an EF of 39% ( Figure 1 ). Coronary artery disease was excluded by invasive coronary angiography. Serum aldosterone was 18.7 ng/dL, plasma renin activity was 0.06 ng/mL, which gave SA/PRA >20, and intravenous normal saline infusion test failed to suppress serum aldosterone, which confirmed the diagnosis of primary hyperaldosteronism. Table 1 ).
Discussion
To date, aldosteronoma has not been reported as a cause for dilated cardiomyopathy. Despite positive clinical effects of sacubitril-valsartan in dilated cardiomyopathy, about 10% of the treated patients are non-responders. Sacubitril/valsartan lowers morbidity and mortality more efficiently than enalapril in patients with heart failure with reduced EF. 6, 7 However, in hyperaldosteronism treatment with sacubitril/valsartan plus drug therapy with furosemide, metoprolol, and spirolactone for 1 year with well-controlled hypertension failed to improve LV function. Only 2 months after the aldosteronoma removal, the left ventricle systolic function recovered (EF 52%) and the LV diameter normalized (LV-ED 40 mm). Excess aldosterone stimulates activated macrophages to release galectin-3 and interacts with the interleukin-33/ST2 signalling pathway, both representing major markers and mediators of myocardial fibrosis, which, in turn, activates pathways involved in cell growth, collagen formation, and inflammation. In addition, animal experiments demonstrated the damage leading to tissue hypertrophy and fibrosis of aldosterone on left ventricle. [8] [9] [10] Through this case, we propose hyperaldosteronism as 
Conclusion
This case of aldosteronism-induced DCM confirms a key role for surgical removal of the aldosteronoma to improve LV function. There is a probable causal relationship between dilated cardiomyopathy and aldosteronoma, and in patients unresponsive to angiotensin receptor inhibitors or sacubitril/valsartan. Hyperaldosteronism should be excluded as a potential cause of DCM. 
